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Paracetamol, metoclopramide, morphine sulfate 
are formulated as paediatric oral solutions (Table 
1);  salbutamol and loratadine as oral syrups;
(Table 2) and various antibiotics as powders and 
granules for oral suspensions. Most medicines are 
marketed as tablets and capsules for older 
children, while only analgesics and multivitamin 
supplements as flexible solid dosage forms.  
The paediatric drug development is associated 
with numerous challenges. As a result, only a 
fraction of all medicines are licensed for use in 
children globally. 
Traditional oral solid medicines are frequently 
used in children, mostly due to their stability, 
dose uniformity and costs. 
On the other hand, novel oral dosage forms offer 
dose flexibility and individualized therapy on the 
basis of paediatric age groups and inter-
individual variations. Such novel oral 
formulations include mini-tablets, chewable and 
orodispersible tablets, and dosage forms 
dispersible into liquids or mixed with food. 
The inadequate marketing of paediatric 
medicines is of concern especially in countries 
with limited healthcare budgets, impeding patient 
access to innovative products with tangible 
therapeutic benefits.
Our information resource included the National 
Register Medicinal Products, published by the 
Macedonian Drug Agency in 2012. 
We studied oral paediatric medicines formulated 
as traditional and novel dosage forms, and 
illustrated the therapeutic areas with no pediatric 
medicines available.
Our aim was to study paediatric oral dosage 
forms marketed in the Republic of Macedonia, 
and determine classes of medicines without 
paediatric friendly formulations.
Paediatric medicines are available in 
different varieties on the Macedonian 
market, predominantly as tablets, capsules, 
syrups and powders and granules for 
suspensions. 
The insufficient availability of child friendly 
formulations in certain therapeutic areas 
reflects the difficulties in developing such 
formulations and penetrating the markets 
with limited national budgets. 
PurposeMeth ds
Generic name 
(concentration)
Therapeutic group
Paracetamol (30mg/ml) non-opoid analagesic
Pholcodine (5mg/5ml) cough suppressant
Butamirate (4mg/5ml) cough suppressant
Metoclopramide (5mg/5ml) antiemetic
Ferrous (II) succinate 
(800mg/15ml)
antianemic
Morphine sulfate (10mg, 
30mg, 100mg/5ml)
opioid analgesic
Salbutamol (2mg/5ml) bronchospasmolitic
Table 2: Examples of Paediatric Syrups
Generic name 
(concentration)
Therapeutic group
Etosuximide 250mg/ml) antiepileptic
Feniramin
mlaleate(15mg/5ml)
antihystaminic
Loratadine (5mg/5ml) antihystaminic
Ibuprofen (100mg/5ml) NSAID
Paracetamol (120mg/5ml) analgoantipiretic
Trimethoprim/\
sulfamethoxazole
(200mg+40mgmg/5ml)
sulfonamide
Salbutamol 2mg/5ml) bronchospasmolitic
Table 3: Examples of medicines not 
available  in suitable dosage form for 
infants and younger children
Generic name Therapeutic group
Amiodarone, 
Propafenone
antiarrhythmic agent
Amitriptyline,Sertraline antidepressant
Irbesartan, Enalapril, 
Captopril, Minoxidil
antihypertensive
Lansoprazole proton pump inhibitor
Methotrexate cytotoxic agent
Procarbazine antineoplastic agent
Olanzapine antipsychotic agent
Saquinavir antivirotic agent
Spironolactone diuretic 
Tiagabine antiepileptic agent
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Our study illustrated several therapeutic 
areas with limited availability of paediatric 
medicines  in Table 3 (antiarrhythmics, 
antihypertensives, proton pump inhibitors, 
H2-receptor antagonists, antiasthmatics, 
antidepressants, etc).
